

1 **Human influenza virus infection elicits distinct patterns of monocyte and dendritic cell**  
2 **mobilization in blood and the nasopharynx**

3

4 S. Vangeti<sup>1</sup>, S. Falck-Jones<sup>1</sup>, M. Yu<sup>1</sup>, B. Österberg<sup>1</sup>, S. Liu<sup>1</sup>, M. Asghar<sup>2,3</sup>, K. Sondén<sup>2,3</sup>, J. Albert<sup>4,5</sup>, N.  
5 Johansson<sup>2,3</sup>, A. Färnert<sup>2,3</sup> and A. Smed-Sörensen<sup>1\*</sup>

6

7 <sup>1</sup>Division of Immunology and Allergy, Department of Medicine Solna, Karolinska Institutet, Karolinska  
8 University Hospital, Stockholm, Sweden. <sup>2</sup>Division of Infectious Diseases, Department of Medicine  
9 Solna, Karolinska Institutet, Sweden. <sup>3</sup>Department of Infectious Diseases, Karolinska University  
10 Hospital, Stockholm, Sweden. <sup>4</sup>Department of Microbiology, Tumor and Cell Biology, Karolinska  
11 Institutet, Stockholm, Sweden. <sup>5</sup>Department of Clinical Microbiology, Karolinska University Hospital,  
12 Stockholm, Sweden.

13

14

15 \*Correspondence to: Dr. Anna Smed-Sörensen, Division of Immunology and Allergy, Department of  
16 Medicine Solna, Karolinska Institutet, NKS BioClinicum J7:30, Visionsgatan 4, 171 64 Stockholm,  
17 Sweden.

18 Phone: +46 73 712 1641. E-mail: [anna.smed.sorensen@ki.se](mailto:anna.smed.sorensen@ki.se).

19

20 **KEYWORDS:** Influenza A virus infection, nasopharynx, dendritic cells, intermediate monocytes, TNF $\alpha$ .

21 **RUNNING TITLE:** Monocytes and DCs in the nasopharynx in IAV infection

22 **ABSTRACT**

23 During respiratory viral infections, the precise roles of monocytes and dendritic cells (DCs) in the  
24 nasopharynx in limiting infection and influencing disease severity are incompletely described. We  
25 studied circulating and nasopharyngeal monocytes and DCs in healthy individuals and in patients with  
26 mild respiratory infections (primarily influenza A virus, IAV). As compared to healthy controls (HCs),  
27 patients with acute IAV infection displayed reduced DC but increased intermediate monocytes  
28 frequencies in blood, and an accumulation of most monocyte and DC subsets in the nasopharynx. IAV  
29 patients had more mature monocytes and DCs in the nasopharynx, and higher levels of TNF $\alpha$ , IL-6 and  
30 IFN $\alpha$  in plasma and the nasopharynx. In blood, monocytes, the most frequent cellular source of TNF $\alpha$   
31 during IAV infection, remained responsive to additional stimulation with TLR7/8L. Immune responses in  
32 older patients skewed towards increased monocytes rather than DCs suggesting a contributory role for  
33 monocytes in disease severity. In patients with other respiratory virus infections, we observed changes  
34 in monocyte and DC frequencies in the nasopharynx distinct from IAV patients, while differences in  
35 blood were more similar across patient groups. Together, our findings demonstrate tissue-specific and  
36 pathogen-specific patterns of monocyte and DC function during human respiratory viral infections and  
37 highlight the importance of comparative investigations in blood and the nasopharynx.

## 38 INTRODUCTION

39 Respiratory viral infections cause significant global disease burden with influenza, or flu, being  
40 responsible for a significant portion. An estimated 1 billion cases of influenza occur annually resulting in  
41 approximately 3-5 million severe cases and 290,000-650,000 deaths (1). In addition to seasonal  
42 epidemics caused by both influenza A or B virus (IAV and IBV, respectively), IAV can also cause  
43 pandemics. The majority of infections remain asymptomatic or develop mild to moderate respiratory  
44 disease, characterized by fever, nasal congestion, cough, and muscle aches. Severe disease mainly  
45 affects infants, pregnant women, and the elderly or immunocompromised, but can also occur in  
46 otherwise healthy individuals (2, 3). The determinants of disease severity are still incompletely  
47 understood but may include properties of the virus, environmental factors, genetics, and immune  
48 responses of the patient (4, 5). Other agents causing an influenza-like illness during influenza season  
49 include respiratory syncytial virus (RSV) and seasonal coronaviruses (OC43, HKU1, 229E, and NL63).  
50 Similar to IAV, coronaviruses are capable of causing pandemics, most notably the ongoing coronavirus  
51 disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-  
52 2) (6).

53  
54 IAV is primarily transmitted via inhalation of virus-containing aerosols or droplets, and mainly targets  
55 respiratory epithelial cells (7, 8), with the nasopharynx being the initial site of virus replication. IAV  
56 generally remains localized to the airways, despite signs of systemic inflammation (9). At the site of  
57 infection, resident innate immune cells including monocytes and dendritic cells (DCs) rapidly respond to  
58 the presence of virus by secreting cytokines, interferons, and chemokines to limit viral spread and recruit  
59 immune cells (10, 11). Monocytes and DCs shape the specificity and strength of the subsequent  
60 adaptive responses (12, 13). In blood, three subsets of monocytes are found: the CD14+CD16-  
61 classical monocytes (CMs), the most frequent subset at steady state, and the further differentiated  
62 CD14+CD16+ intermediate monocytes (IMs) and CD14-CD16+ nonclassical monocytes (NCMs) (14-  
63 16). Blood IMs expand rapidly in response to inflammation, infection, or vaccination (3, 12, 17). In  
64 addition, monocytes extravasate to tissue where they play an important role in innate immune protection.  
65 Monocytes also secrete TNF $\alpha$ , a major regulator of innate immune function that is central to the cytokine  
66 storm associated with IAV infection (18). Of the DCs, the CD1c+ myeloid DCs (MDCs) excel at activating  
67 naïve T cells (19); the CD141+ MDCs can cross-present antigens via MHC-I (20); and the CD123+

68 plasmacytoid DCs (PDCs) mediate type I IFN responses (21). Monocytes and DCs vary in distribution  
69 and function, depending on the anatomical compartment (22, 23). Moreover, monocytes and DCs are  
70 susceptible to IAV infection in vitro, and the cytopathic nature of the virus may impair their antigen  
71 processing and presenting functions (24-26), delaying recovery and normalization of immune cell  
72 distribution and function (27, 28) .

73  
74 Studies have shown that monocytes and DCs are recruited to the nasopharynx following infection with  
75 2009 H1N1pdm IAV strains (3), and in individuals hospitalized with severe influenza infections (29, 30).  
76 Disease severity in hospitalized patients has been shown to correlate with (i) monocyte recruitment and  
77 increased levels of MCP3, IFN $\alpha$ -2 and IL-10 in the nasal compartment (3) and (ii) strong TNF-producing  
78 monocytic responses in blood (2) and inflammatory, neutrophil-dominant patterns (31). Despite  
79 accounting for a comparatively greater burden of disease, immune responses during mild seasonal  
80 influenza infections remain less studied. Therefore, the roles played by monocytes and DCs in  
81 contributing to or mitigating mild influenza disease are largely unknown. Additionally, while the response  
82 of blood monocytes and DCs to IAV has been studied well in vitro and in animal models (24, 25, 27, 32-  
83 35), few studies compare responses between blood and the nasopharynx in human infections (31, 32,  
84 36). Immune cell behaviour in the nasopharynx during IBV and RSV infections has not been studied in  
85 great detail but evidence of DC mobilization to the nasal cavity has been reported (29). Studies on  
86 immune responses to mild SARS-CoV-2 infection have also primarily focused on blood and rarely the  
87 upper airways (37).


88  
89 Here, we determined monocyte and DC subset distribution, maturation and function in both blood and,  
90 for the first time, the nasopharynx, in patients with mild to moderate seasonal influenza and influenza-  
91 like infections. The methods described in this study allowed us to investigate airway immunity in a larger  
92 cohort of patients with SARS-CoV-2 infection (38, 39), showing that methods to study the immune  
93 responses in the nasopharynx during acute disease are essential tools as we face the possibility of  
94 future pandemics. Comparing the dynamics of systemic and nasopharyngeal immune function will add  
95 to our understanding of the roles of monocytes and DCs in shaping the nature and magnitude of  
96 inflammation and subsequently disease severity during respiratory viral infections.

97 **RESULTS**

98 **Study subject characteristics**

99 During three consecutive influenza seasons (2016-2018), 84 adults with symptoms of influenza-like  
 100 illness (ILI) were included in the study. Blood, nasal swabs and nasopharyngeal aspirates were collected  
 101 (Figure 1A). IAV infection was confirmed by PCR in 40 patients while 44 patients had other infections  
 102 (IBV: 10, RSV: 6, other viruses: 2, bacteria: 3 and unknown aetiology: 23) despite presenting with similar  
 103 symptoms (Figure 1B), consistent with inclusion based on ILI. Patients with bacterial infection, other  
 104 viral infection or infections of unknown etiology were excluded from further analysis leaving 56 patients  
 105 with confirmed IAV, IBV or RSV infection. The severity of disease in patients was categorized as “mild”  
 106 or “moderate” (detailed description in Methods). Of the 56 IAV/IBV/RSV patients, 8 had moderately  
 107 severe disease and 21 were hospitalized (Table 1). During the COVID-19 pandemic in 2020, we  
 108 included 8 adults with PCR+ SARS-CoV-2 infection (7 with mild and 1 with moderate disease) for this  
 109 study based on the availability of paired blood and NPA samples from the time of inclusion. Sixteen  
 110 healthy controls (HCs) were included and sampled identically as patients.

Figure 1



111  
 112 **Figure 1. Cellular infiltration into the nasopharynx during IAV infection is largely due to**  
 113 **accumulation of  $\text{lin}^{-}\text{HLA-DR}^{+}$  cells.** (A) Nasal swabs, nasopharyngeal aspirates (NPA), and  
 114 peripheral blood samples were collected from patients with acute symptoms of influenza-like symptoms

115 and during their convalescence as well as from healthy controls (HCs). **(B)** 40 of 64 patients with  
116 influenza-like symptoms were confirmed to be infected with influenza A virus (IAV) by PCR and were  
117 included in the study. Immunological analyses were performed on acute (n=40) and convalescent (n=11)  
118 samples from the IAV patients and HC (n=16). IAV patients with mild disease, as defined by peak  
119 respiratory SOFA or mSOFA score of 1 or 2 are indicated in black and those with moderate disease  
120 (mSOFA score of 3 or 4) are indicated in pink. **(C-E)** Scatter plots show data from individual subjects  
121 and lines indicate median values. Patients with mild disease are indicated in black and those with  
122 moderate disease are indicated in pink. **(C)**  $\times 10^6$  PBMCs (per mL blood, filled circles) and  $\times 10^6$  total  
123 NPA cells (open circles) obtained from IAV patients and HCs. **(D)** Cell viability of PBMCs and NPA from  
124 patients and HCs was assessed using trypan blue exclusion staining and manual counting. **(E)**  
125 Frequency of lin<sup>-</sup>HLA-DR<sup>+</sup> cells (monocytes and myeloid dendritic cells) of live CD45<sup>+</sup> cells in blood  
126 and NPA from HCs (n=16) and IAV patients (n=22). Differences between IAV patients and HCs were  
127 assessed using Mann-Whitney test and considered significant at  $p < 0.05$  (\*\* $p < 0.01$ , \*\*\*\* $p < 0.0001$ ).

128  
129 IAV patients had a mean age of 59 (range: 20-98 years) and on average sought medical attention 3.3  
130 days after the onset of symptoms (SD: 2.1 days) (Table 1). HCs had slightly lower mean age of 46  
131 (range: 28-59 years). IAV patients had a mean Charlson co-morbidity index (CCI) of 2.46 (SD: 2.22),  
132 and 36 IAV patients had at least one underlying comorbidity (chronic heart/lung diseases, reduced lung  
133 function, kidney insufficiency, diabetes mellitus, asplenia/hyposplenia and malignancies).

134

Cohort	IAV	IBV	RSV	SARS-CoV-2	HC	Sig. <sup>A</sup>
<i>n</i>	40	10	6	8	16	
Age, mean (range)	59 (20-98)	53 (25-89)	61 (32-88)	44 (29-66)	46 (28-59)	0.068
Male gender, <i>n</i> (%)	18 (45)	6 (60)	2 (33)	4 (50)	8 (50)	0.9
Onset to inclusion, days, mean (SD)	3.3 (2.1)	5.0 (1.3)	6.5 (2.6)	13.2 (7.8)	-	<0.001
Hospital admission, <i>n</i> (%)	15 (38)	2 (20)	4 (67)	2 (25)	-	0.3
<b>Co-morbidities</b>						
CCI, mean (SD)	2.46 (2.22)	1.44 (1.81)	3.50 (3.83)	0.88 (1.36)	-	0.12
BMI, mean (SD)	27.1 (4.8)	26.5 (5.8)	26.5 (4.7)	26.1 (3.6)	-	>0.9
Hypertension, <i>n</i> (%)	9 (22)	1 (10)	2 (33)	2 (25)	-	0.7
Diabetes, <i>n</i> (%)	3 (7.5)	2 (20)	2 (33)	2 (25)	-	0.1
Current smoker, <i>n</i> (%)	5 (14)	1 (11)	0	0	-	>0.9
<b>Laboratory analyses</b>						
CRP (mg/L), mean (SD)	41 (35)	60 (85)	47 (21)	26 (37)	1 (1)	0.009
WBC (x10 <sup>9</sup> /L), mean (SD)	7.07 (2.45)	7.00 (2.92)	8.78 (2.49)	5.67 (2.24)	6.24 (1.28)	0.14
Lymphocytes (x10 <sup>9</sup> /L), mean (SD)	1.08 (0.86)	0.89 (0.33)	1.1 (NA)	1.64 (0.67)	1.7 (0.37)	0.2
Neutrophils (x10 <sup>9</sup> /L), mean (SD)	5.14 (2.18)	5.41 (3.13)	5.6 (NA)	3.19 (1.85)	3.62 (1.21)	0.3
Monocytes (x10 <sup>9</sup> /L), mean (SD)	0.75 (0.32)	0.53 (0.11)	0.8 (NA)	0.56 (0.23)	0.45 (0.06)	0.14
Ct-value, mean (SD)	27.0 (6.1)	27.8 (7.1)	30.9 (6.0)	25.4 (5.8)	-	0.4
<b>Treatment</b>						
Tamiflu prescribed, <i>n</i> (%)	18 (45)	0	0	0	-	-
Antibiotics prescribed, <i>n</i> (%)	8 (21)	2 (22)	3 (50)	0	-	0.3
<b>Peak severity score</b>						
Mild disease, <i>n</i> (%)	34 (85)	10 (100)	4 (67)	7 (88)	-	0.3
Moderate disease, <i>n</i> (%)	6 (15)	0	2 (33)	1 (12)	-	0.3


135 **Table 1. Patient and control characteristics.** <sup>A</sup>Statistical significance was determined by 1-way  
136 ANOVA, Fisher's exact test, or Pearson's  $\chi^2$  test. CCI: Charlson Comorbidity Index. BMI: Body Mass  
137 Index. CRP: C-reactive protein. WBC: White Blood Cells. Ct: Cycle threshold. Normal range: BMI: 18.5  
138 to 24.9, CRP <3 mg/L, WBC  $3.5 \times 10^9/L$  to  $8.8 \times 10^9/L$ , lymphocytes  $1.1 \times 10^9/L$  to  $3.5 \times 10^9/L$ , neutrophils  
139  $1.6 \times 10^9/L$  to  $5.9 \times 10^9/L$ , monocytes  $0.2 \times 10^9/L$  to  $0.8 \times 10^9/L$ .

140 **Human IAV infection is characterized by an influx of CD11c+ cells into the nasopharynx**

141 Blood from IAV patients yielded significantly fewer PBMCs/mL compared to HCs (Figure 1C). In  
142 contrast, 3-fold higher cell numbers were recovered from the nasopharynx of IAV patients compared to  
143 HCs (median 0.77 vs. 0.25 x 10<sup>6</sup> cells). In fact, 43% of IAV patients had more than 1 x 10<sup>6</sup> cells recovered  
144 from their NPA sample. Viability of PBMCs and NPA cells was variable across individuals, with no  
145 statistically significant differences between patients or HCs (Figures 1D). We determined the immune  
146 cell distribution in blood and the nasopharynx by flow cytometry (Supplementary Figure 1) on matched  
147 PBMC and NPA samples with a minimum 10<sup>5</sup> cells and ≥70% viability (n=22 IAV patients and n=16  
148 HCs) to obtain high quality data (stained with identical panels and clones of antibodies). The frequencies  
149 of live CD45+ immune cells were increased in the NPA of patients as compared to HCs but remained  
150 similar in blood between the groups (data not shown). Among the immune cells, we found significantly  
151 higher frequencies of lineage (CD3, CD19, CD20, CD56, CD66abce) negative, HLA-DR+ cells, the  
152 compartment where monocytes and myeloid DCs can be identified, in both blood (p<0.0001), and the  
153 NPA (p<0.01) of IAV patients as compared to HCs (Figure 1E). Therefore, our data show that acute IAV  
154 infection results in an influx of monocytes and DCs to the nasopharynx.



## Supplementary figure 1



155

156 **Supplementary Figure 1. Gating strategy for identification of monocytes and dendritic cells from**

157 **PBMCs and NPA.** Representative sample showing gating on live CD45+ single cells, excluding cells

158 expressing lineage markers (CD3, CD20, CD56 and CD66abce) and identification of HLA-DR

159 expressing cells. From the live CD45+, lineage negative, HLA-DR+ (lin<sup>-</sup>HLA-DR<sup>+</sup>) cells, CD11c<sup>-</sup> cells

160 were gated upon to identify CD123+ plasmacytoid DCs (teal). From the CD11c+ myeloid cells, classical  
161 (CD14+CD16-) (green), intermediate (CD14+CD16+) (red) and non-classical (CD14-CD16+) (blue)  
162 monocytes were identified. From CD14-CD16- cells, two myeloid DC subsets CD1c+ (coral) and  
163 CD141+ (maroon) were identified. Representative samples of using the antibody panel and gating  
164 strategy to analyze all 6 subsets (CMs, IMs, NCMs, PDCs, CD1c+ MDCs and CD141+ MDCs) in blood  
165 samples from a (A) HC and (B) IAV patient and NPA samples from a (C) HC and (D) IAV patient are  
166 shown.


167

### 168 **Increased frequencies of classical and intermediate monocytes in the nasopharynx during IAV** 169 **infection**

170 To identify which monocyte subsets contributed to the changes observed during IAV infection, we  
171 analyzed the distribution of the different monocyte subsets (Figure 2A). As expected, CMs were the  
172 most frequent monocytes in blood in both patients and HCs, and remained comparable. However, in  
173 the nasopharynx of IAV patients as compared to HCs, blood CM frequencies were significantly  
174 increased (Figure 2B). Strikingly, IM frequencies were significantly elevated, in both blood and NPA of  
175 IAV patients (Figure 2C), while blood NCM appeared to be lower in patients compared to HCs (Figure  
176 2D). Comparing frequencies of monocytes in blood and NPA in the same individual (Figure 2E)  
177 illustrates that IAV infection disrupts the pattern of monocyte distribution in the two anatomical  
178 compartments seen in healthy individuals- primarily in CMs and IMs. The frequencies of IMs in blood  
179 and NPA, and of the CMs in the NPA (solid lines) displayed greatest fluctuation from HCs (dashed line)  
180 at fewer days with symptoms (Figures 2F-G). This suggests that changes in the monocyte compartment  
181 may occur earlier in the course of infection but these findings should be interpreted with caution since  
182 they are based on a single acute phase sample from each patient. In future studies, longitudinal  
183 sampling of the same patient would allow for mapping kinetics of monocyte redistribution over the course  
184 of acute IAV infection and convalescence. We also compared the frequency of IMs in blood and  
185 nasopharynx with the age of IAV patients and found a negative correlation in blood ( $R=-0.55$ ,  $p=0.0008$ )  
186 (Figure 2H) but a positive correlation in the nasopharynx ( $R=0.46$ ,  $p=0.045$ ) (Figure 2I). In HCs, age and  
187 IM frequencies were not significantly correlated in blood or NPA (data not shown). A subset of IAV  
188 patients ( $n=11$ ) returned for sampling during convalescence ( $\geq 4$  weeks after initial sampling). We  
189 observed that frequencies of CMs (in blood) and IMs (blood and NPA) in convalescent individuals were

190 reduced and closer to values seen in HCs (Figure 2J). Collectively, we found that the increased immune  
191 cell presence in the nasopharynx during acute IAV infection could be, to a large extent, attributed to  
192 increased frequencies of IMs as well as CMs which normalized during convalescence. Acute IAV  
193 infection resulted in altered monocyte distribution, in particular at the site of infection and was more  
194 pronounced in older patients.

Figure 2



195  
196 **Figure 2. Higher frequencies of intermediate monocytes in blood and the nasopharynx from IAV**  
197 **patients compared to healthy controls. (A)** Contour plots show CD14+CD16–classical monocytes  
198 (CMs, green), CD14+CD16+ intermediate monocytes (IMs, red) and CD14–CD16+ non-classical  
199 monocytes (NCMs, blue) in blood (top) and NPA (bottom) from one representative HC and one  
200 representative IAV patient determined by flow cytometry. **(B-D)** Scatter plots show frequencies of **(B)**

201 CMs, (C) IMs and (D) NCMs in PBMCs and NPA from HCs (n=12) and IAV patients (n=22). Graphs  
202 show data from individual subjects and lines represent median values. Differences between IAV patients  
203 and HCs were assessed using Mann-Whitney test and considered significant at  $p < 0.05$  (\*\* $p < 0.001$ ,  
204 \*\*\*\* $p < 0.0001$ ). (E) displays frequencies of monocyte subsets from B-D again, with lines connecting  
205 values in blood (filled circles) and NPA (open circles) in the same individual. (F-G) Temporal changes  
206 in CM and IM frequencies as a function of days with symptoms. Solid lines illustrate the trend for CMs  
207 (green) and IMs (red) in (F) blood and (G) NPA of IAV patients as compared to median values observed  
208 in HCs (dashed lines). (H-I) Scatter plots and line of fit display bivariate linear regression analysis  
209 between age and IM frequency in (H) blood and (I) NPA of IAV patients. The shaded area represents  
210 the 95% confidence region for the fitted line. R represents Spearman  $\rho$  and differences were considered  
211 significant at  $p < 0.05$ . (J) Graphs depict frequencies of CMs (green) and IMs (red) in blood (n=8) and the  
212 NPA (n=6) in the acute (upward triangles) and convalescent phase (downward triangles) in IAV patients.  
213 Dashed lines depict median frequency values from HCs in blood and NPA. Differences between acute  
214 and convalescent phase values were assessed using Wilcoxon matched-pairs signed rank test and  
215 considered significant at  $p < 0.05$  (\* $p < 0.05$  and \*\* $p < 0.01$ ).


216

### 217 **Dendritic cell subsets infiltrate the nasopharynx during IAV infection**

218 DCs may also account for redistribution in the myeloid cell compartment. In HCs, the nasopharynx was  
219 virtually devoid of DCs, and CD1c+ MDCs, CD141+ MDCs and plasmacytoid DCs (PDCs) were only  
220 identified in a subset of HCs (Supplementary figure 1 and Figure 3A). In contrast, during acute IAV  
221 infection, all DC subsets were significantly increased in the nasopharynx of patients (Figure 3B-D).  
222 Meanwhile in blood, DC frequencies decreased significantly in IAV patients compared to HCs (Figures  
223 3B-D). This reciprocal pattern is further illustrated by comparing the DC frequencies in blood and NPA  
224 in the same individual (Figure 3E). Looking over days of symptoms, the frequencies of DCs in blood  
225 remained lower in IAV patients (solid lines) as compared to HCs (dashed lines) throughout the sampling  
226 window (0-9 days with symptoms), with the most striking reduction evident at the earliest times (Figures  
227 3F-G). Conversely in the nasopharynx, DC frequencies in patients fluctuated over time but remained  
228 higher than in controls. In contrast to IMs, we found an inverse correlation between age and the  
229 frequency of CD1c+ MDCs in NPA ( $R = -0.558$ ,  $p = 0.016$ ) in IAV patients (Figure 3H). During  
230 convalescence, CD1c+ MDC frequencies were increased in blood and lowered in nasopharynx (Figure

231 3l). Taken together, we showed that the DC compartment also underwent substantial changes in both  
 232 blood and the nasopharynx during acute IAV infection, potentially suggesting that DCs also received  
 233 signals to induce migration and/or maturation.

Figure 3



234  
 235 **Figure 3. Lower frequencies of dendritic cells in blood but higher frequencies in the nasopharynx**  
 236 **in IAV patients compared to healthy controls. (A)** Scatter plots shows the frequencies of CD1c+  
 237 (coral) and CD141+ (maroon) myeloid DCs (MDCs); and CD123+ PDCs (teal) in the NPA from HCs  
 238 (n=16). Lines indicate median frequencies. Graphs show frequencies of (B) CD1c+ MDCs, (C) CD141+  
 239 MDCs and (D) CD123+ PDCs expressed as a frequency of lin-HLA-DR+ cells in PBMCs and NPA from  
 240 HCs (n=12) and IAV patients (n=22). Shaded bars represent median values. Differences between IAV  
 241 patients and HCs were assessed using Mann-Whitney test and considered significant at  $p < 0.05$


242 (\*\* $p < 0.01$ , \*\*\* $p < 0.001$ , \*\*\*\* $p < 0.0001$ ). (E) displays frequencies of DC subsets from B-D again, with lines  
243 connecting values in blood (filled circles) and NPA (open circles) in the same individual. (F-G) Temporal  
244 changes in DC subset frequencies as a function of days with symptoms. Solid lines illustrate the  
245 temporal variation in the frequencies of PDCs (teal), CD1c+ MDCs (coral) and CD141+ MDCs (maroon)  
246 in (F) blood and (G) NPA of IAV patients as compared to median values observed in HCs (dashed lines).  
247 (H) Scatter plot and line of fit display bivariate linear regression analysis between age and frequency of  
248 CD1c+ MDCs in blood. The shaded area represents the 95% confidence region for the fitted line. R  
249 represents Spearman  $\rho$  and differences were considered significant at  $p < 0.05$ . (I) Graph depicts  
250 frequencies of CD1c MDCs (coral) in blood ( $n=8$ ) and the NPA ( $n=6$ ) in the acute (upward triangles) and  
251 convalescent phase (downward triangles) in IAV patients. Dashed lines depict median frequency values  
252 from HCs in blood and NPA. Differences between acute and convalescent phase values were assessed  
253 using Wilcoxon matched-pairs signed rank test and considered significant at  $p < 0.05$  (\* $p < 0.05$ ).

254

### 255 **Monocytes and DCs recruited to the human nasopharynx during IAV infection are more mature**

256 We next analyzed the maturation status of DCs and monocytes in blood and nasopharynx samples from  
257 IAV patients and HCs (Figure 4A-D). Cells from HCs had low and comparable levels of surface HLA-  
258 DR in both blood and the nasopharynx (Figure 4A). In contrast, in IAV patients, monocytes and DCs in  
259 the nasopharynx expressed higher levels of HLA-DR than those in blood (Figure 4A and C). We also  
260 found that in IAV patients, nasopharyngeal CD1c+ MDCs and CD141+ MDCs expressed more CD86  
261 than cells in blood (Figure 4D), while nasopharyngeal PDCs showed significant upregulation of CD83  
262 during IAV infection as compared to blood PDCs (Figure 4E). When we compared maturation of CM  
263 and MDCs (i.e., CD86 expression) with viral RNA load (i.e., Ct values- number of cycles required to  
264 amplify viral RNA), we observed a significant inverse correlation ( $R = -0.696$ ,  $p = 0.0019$ ), implying that  
265 higher viral RNA loads (low Ct value) were associated with increased maturation of CMs (Figure 4F).  
266 We also observed a positive correlation between CD86 expression on nasopharyngeal CMs, and both  
267 nasopharyngeal CD1c+ MDCs ( $R = 0.735$ ,  $p = 0.0012$ ) and CD141+ MDCs ( $R = 0.832$ ,  $p = 0.0001$ ) (Figures  
268 4G and H, respectively). This indicates that in patients with greater viral RNA load who also have more  
269 mature CMs in the nasopharynx, there is a greater likelihood of finding mature MDCs in the nasopharynx  
270 as well.

Figure 4



271

272 **Figure 4. Intermediate monocytes and MDCs in the nasopharynx are more mature in IAV patients**

273 **than in healthy controls. (A-D)** Scatter plots depict MFI of (A, C) HLA-DR and (B, D) CD86 surface

274 expression on (A-B) monocyte and (C-D) DC subsets in blood (filled circles) and in the NPA (open

275 circles) in HCs (left, n=11) and IAV patients (right, n= 19). (E) Scatter plot depicts MFI of CD83

276 expression on PDCs in blood (filled circles) and in the NPA (open circles). Differences between IAV

277 patients and HCs were assessed by Mann-Whitney test and considered significant at  $p < 0.05$ . (\* $p < 0.05$ ,

278 \*\* $p < 0.01$ , \*\*\* $p < 0.001$  and \*\*\*\* $p < 0.0001$ ). (F-H) Scatter plots and lines of fit display bivariate linear

279 regression analysis between monocyte maturation status (CD86 surface expression (MFI)) of NPA CMs

280 in IAV + patients and (F) Ct values, (G) maturation status (CD86 surface expression (MFI)) of NPA

281 CD1c+ MDCs in IAV patients and (H) maturation status (CD86 surface expression (MFI)) of NPA

282 CD141+ MDCs in IAV patients. The shaded area represents the 95% confidence region for the fitted


283 line. R represents Spearman  $\rho$  and differences were considered significant at  $p < 0.05$ .

284 **Elevated cytokine levels observed in plasma and the nasopharyngeal secretions correlate with**  
285 **increased monocyte frequencies in respective compartment**

286 Pronounced cytokinemia is a hallmark of severe influenza disease (18). In order to characterize the  
287 degree of inflammation in IAV patients, we measured local and systemic cytokine levels. In agreement  
288 with earlier reports (2, 3, 29, 30), we observed elevated levels of  $TNF\alpha$ , IL-6 and  $IFN\alpha$  in nasopharyngeal  
289 secretions (Figures 5A-C) as well as in plasma of IAV patients as compared to HCs (Figures 5D-F). We  
290 also observed elevated levels of plasma IL-10, IL-15 and IL-18 in IAV patients as compared to HCs  
291 (data not shown). We compared soluble  $TNF\alpha$  levels against frequencies of monocytes and DCs (i.e.,  
292 potential cellular sources) at the respective anatomical sites; and found a positive correlation between  
293 soluble  $TNF\alpha$  and CM frequency, both in blood (Figure 5G); and in the nasopharynx of IAV patients  
294 (Figure 5H). However, such correlation was not observed for DCs in blood or NPA (data not shown).  
295 Interestingly, we also observed positive associations between age and level of  $TNF\alpha$  in plasma and  
296 NPA in IAV patients (Figure 5I). Furthermore, we observed that plasma  $IFN\alpha$  levels were positively  
297 correlated with Ct value (suggesting inverse correlation with viral RNA load) (Figure 5J). Patients with  
298 higher viral RNA loads had lower amounts of  $IFN\alpha$  in circulation, which may suggest incomplete  
299 protection from infection. For a subset of patients, we assessed chemokines (CCL2, CCL3 and CCL7)  
300 in circulation and at the site of infection. Interestingly, in blood, elevated plasma levels of CCL2  
301 correlated positively with IM frequencies, which were significantly elevated in IAV patients, indication a  
302 role for CCL2 in the changes to the IMs during infection (Figure 5K). Moreover, during convalescence,  
303  $TNF\alpha$  and IL-6 were also reduced both in the nasopharynx and in blood suggesting ablation of both  
304 local and systemic inflammation (Figures 5L).



Figure 5



305

306

307

308

309

310

311

312

313

314

315

316

**Figure 5. Nasopharyngeal and plasma levels of proinflammatory cytokines TNF $\alpha$ , IL-6 and IFN $\alpha$  are elevated during acute IAV infection. (A-F)** Graphs show concentrations of (A and D) TNF $\alpha$ , (B and E) IL-6, (C and F) IFN $\alpha$  in (A-C) NPA (open circles) and (D-F) plasma (filled circles) from HCs (n=12) and IAV patients (n=31) as determined by ELISA. Lines indicate median concentration. Differences between IAV patients and HCs were assessed using Mann-Whitney test and considered significant at  $p < 0.05$  (\* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\*\* $p < 0.0001$ ). (G-K) Scatter plots and lines of fit display bivariate linear regression analysis between variables. The shaded area represents the 95% confidence region for the fitted line. R represents Spearman  $\rho$  and differences were considered significant at  $p < 0.05$ . (G) Log<sub>10</sub> plasma TNF $\alpha$  values vs CM frequency in blood of IAV patients; (H) log<sub>10</sub> NPA TNF $\alpha$  vs CM frequency in the NPA of IAV patients; (I) age vs log<sub>10</sub> TNF $\alpha$  values in plasma (pink) and NPA (blue) in IAV patients; (J) Ct values vs log<sub>10</sub> IFN $\alpha$  values in IAV patients (light green) and (K) log<sub>10</sub>


317 plasma CCL2 vs IM frequency in blood of IAV patients. (L) Graphs depicts TNF $\alpha$  and IL-6 levels in the  
318 NPA (n=4) and plasma (n=8) during the acute (upward triangles) and convalescent phase (downward  
319 triangles) in IAV patients. Dashed lines depict median frequency values from HCs in blood and NPA.  
320 Differences between acute and convalescent phase values were assessed using Wilcoxon matched-  
321 pairs signed rank test and considered significant at  $p < 0.05$  (\* $p < 0.05$  and \*\* $p < 0.01$ ).

322

### 323 **Monocytes are a potent source of systemic TNF $\alpha$ during IAV infection**

324 The localization of mature monocytes and DCs in the nasopharynx during IAV infection, and increased  
325 cytokine levels in both compartments led us to question whether the cells in circulation were directly  
326 involved in inflammation during ongoing infection, or primarily provided a cache of differentiated cells  
327 that can migrate to the site of infection. Limited by the number of viable cells obtained from the  
328 nasopharynx, we tested the functional response of circulating monocytes and DCs to in vitro stimulation  
329 with a TLR7/8 agonist which mimics ssRNA and then quantified the frequency of TNF-producing cells  
330 in each monocyte and DC subset (Figures 6A and B). We observed that blood monocytes and DCs from  
331 IAV patients produced TNF $\alpha$  spontaneously, in the absence of any external stimulus, with most of the  
332 cytokine coming from monocytes (CMs > IMs > NCMs) (Figure 6C). In contrast, blood monocytes and  
333 DCs from HCs only produced TNF $\alpha$  upon stimulation with TLR7/8L (Figure 6D). Importantly, while many  
334 of the IAV patients had cells producing TNF $\alpha$  spontaneously, monocytes and DCs remained responsive  
335 and had the potential for further increased frequency of TNF-producing cells in response to TLR7/8L  
336 stimulation (Figure 6D). In summary, our data suggest that during IAV infection, mature monocytes and  
337 DCs accumulate in the nasopharynx, and blood monocytes and DCs function as a general source of  
338 TNF $\alpha$ , potentially contributing to the systemic inflammatory effects accompanying influenza infections.

Figure 6



339  
 340 **Figure 6. Monocytes and DCs from IAV patients produce TNF $\alpha$  ex vivo without stimulation. (A)**  
 341 TNF $\alpha$  release assay: the capture antibody (green) immobilizes secreted TNF $\alpha$  on the cell surface of the  
 342 TNF $\alpha$ -secreting cell. The PE-labelled detection antibody (pink) together with the phenotypic antibody  
 343 panel allows detection of TNF $\alpha$  production in individual cell subsets by flow cytometry. (Illustrations were  
 344 modified from Servier Medical Art, licensed under a Creative Commons Attribution 3.0 Unported  
 345 License). (B) Representative flow cytometry plots of TNF $\alpha$ -producing blood CMs from one HC after 2  
 346 hours at 37°C without (unstimulated) or with TLR7/8L stimulation. (C) Bar graphs display median  
 347 frequency of TNF $\alpha$ -producing cells in CMs (green), IMs (red), NCMs (blue), PDCs (teal) and total MDCs  
 348 (orange) in blood in HCs (open, n=5) and IAV patients (filled, n=9) in the absence of TLR stimulation.  
 349 Each dot represents an individual donor. (D) Graph displays frequency of TNF $\alpha$ -producing cells in  
 350 monocyte and DC subsets from HCs (open, n=5) and IAV patients (filled n=9) in the absence (-) or  
 351 presence (+) of TLR7/8L stimulation. Differences between IAV patients and HCs in (C) were assessed

352 by Mann-Whitney test and in (D) with two-way ANOVA analysis using Sidak's multiple comparisons test  
353 and considered significant at  $p < 0.05$ . (\* $p < 0.05$ , \*\* $p < 0.01$  and \*\*\* $p < 0.001$ ).

354


355 **Nasopharyngeal aspirates allow assessment of in situ immune responses to mild infections with**  
356 **other respiratory viruses including SARS-CoV-2**

357 In order to determine whether our findings were pathogen-specific to IAV or a reflection of immune  
358 responses to respiratory viral infections in general, we analyzed samples from patients with confirmed  
359 IBV, RSV or SARS-CoV-2 infections. IBV and RSV patients were closer to IAV patients in age (mean:  
360 53 and 61 years, respectively) and days with symptoms (mean: 5.0 and 6.5 days respectively). In  
361 contrast, patients with mild SARS-CoV-2 were younger than IAV patients (mean: 44 years and 59 years  
362 respectively) and sought medical attention later: mean 13.2 days with symptoms (SARS-CoV-2) as  
363 compared to 3.3 days (IAV) (Table 2). Similar to IAV patients, patients with SARS-CoV-2 and RSV had  
364 a higher yield of cells in the nasopharynx than HCs (Figure 7A). The expansion in monocyte and DC  
365 frequencies in blood we saw in IAV patients, was not observed in other infections. Interestingly, in the  
366 nasopharynx, monocytes and DCs were significantly elevated during IAV infection, but not during IBV  
367 infection (Figure 7B). Within the monocyte compartment, we noted differences between the different  
368 pathogens. IMs were not increased during IBV or SARS-CoV-2 infection but were increased during RSV  
369 infection in both blood and the nasopharynx (Figure 7C). The DC compartment too showed differences  
370 between the groups in NPA. In blood, all DC subsets were decreased in all groups (Figure 7D). CD1c+  
371 MDCs were increased in the nasopharynx only during IAV and SARS-CoV-2 infections. Interestingly,  
372 CD141+ MDCs were significantly increased in the nasopharynx only during IAV infection. PDCs in NPA  
373 were increased in all groups.

374

375 In plasma, individuals with SARS-CoV-2 infection had elevated levels of  $\text{TNF}\alpha$  in comparison with HCs  
376 and IAV patients (Figure 7E). SARS-CoV-2 infection was associated with elevated levels of IL-6  
377 compared to HCs, but not compared to the IAV and IBV groups. In NPA, only the IAV and IBV groups  
378 had increased levels of IL-6. Despite having increased frequencies of PDCs in NPA, nasopharyngeal  
379 levels of  $\text{IFN}\alpha$  were not elevated in SARS-CoV-2 patients. Together, these data show different patterns  
380 of monocyte and DC engagement in the nasopharynx and in blood, and also between IAV, IBV, RSV  
381 and SARS-CoV-2, suggesting a requirement for further scrutiny.

Figure 7



382

383 **Figure 7. SARS-CoV-2 infection elicits a distinct pattern of innate immune response as compared**  
 384 **to IAV infection. (A-B)** Scatter plots show data from individual subjects and lines indicate median

385 values. **(A)** Cell yield per mL blood ( $\times 10^6$  PBMCs, filled circles) and total NPA cells ( $\times 10^6$  cells, open  
386 circles) obtained from patients and HCs. **(B)** Frequency of lin<sup>-</sup>HLA-DR<sup>+</sup> cells of live CD45<sup>+</sup> cells in blood  
387 (filled circles) and NPA (open circles) from HCs and patients. **(C-D)** Scatter plots show frequencies of  
388 **(D)** monocyte subsets (CM: green, IM: red, NCM: blue) and **(E)** DC subsets (CD1c<sup>+</sup>: coral, CD141:  
389 maroon, PDC: teal) in PBMCs (filled circles) and NPA (open circles) from HCs and patients. Graphs  
390 show data from individual subjects and lines represent median values. Differences between HCs or IAV  
391 patients and other patient groups were assessed using Kruskal-Wallis test with Dunn's multiple  
392 comparisons test and considered significant at  $p < 0.05$  (\* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$  and  
393 \*\*\*\* $p < 0.0001$ ). **(E)** Graphs show concentrations of TNF $\alpha$ , IL-6 and IFN $\alpha$  in plasma (filled circles) and  
394 NPA (open circles) from HCs and patients as determined by ELISA. Lines indicate median  
395 concentration. Differences between IAV patients and HCs were assessed using Mann-Whitney test and  
396 considered significant at  $p < 0.05$  (\* $p < 0.05$ , \*\* $p < 0.01$  and \*\*\* $p < 0.001$ ).

397 **DISCUSSION**

398 In this study, we mapped monocyte and DC distribution and function in blood and in the nasopharynx  
399 (the initial site of infection) of patients with ongoing IAV, IBV, RSV or SARS-CoV-2 infections and healthy  
400 controls. Several studies have examined immune responses during severe flu, in particular, focusing on  
401 patients sampled during or immediately following the 2009 H1N1 pandemic (2, 3, 31, 40), or patients  
402 hospitalized with severe respiratory symptoms (2, 29-31, 40); and more recently, the immune  
403 dysregulation during severe COVID-19 (41-44). Here, we elucidated the innate myeloid cell composition  
404 and responses in a cohort with relatively mild symptoms, advanced age and underlying comorbidities,  
405 typical of seasonal influenza. Finally, we showed that our methods can be adapted to study immune  
406 responses in other viral infections, including the current COVID-19 pandemic.

407

408 Flow cytometric characterization revealed an influx of monocytes and DCs to the nasopharynx during  
409 infection, in line with previous reports in more severe IAV patients (3, 29, 30, 45). Interestingly, age  
410 appeared to differentially skew the IM response in IAV patients. Despite having higher baseline  
411 frequencies of circulating CD16-expressing monocytes (46), older patients have fewer IMs in blood  
412 during acute IAV infection and concurrently more IMs in the nasopharynx. The increase in IMs suggests  
413 a more inflammatory milieu at the site of infection in older patients, perhaps contributing to disease  
414 severity as previously suggested in pandemic influenza (2-5). Despite the general increase in IM  
415 frequencies, CMs remained the most frequent monocyte/DC subset in either compartment implying a  
416 functional role for CMs during IAV infection. Similar to studies in paediatric patients (29, 30), we also  
417 found that over the course of the illness, DCs appeared to migrate from blood to infiltrate the  
418 nasopharynx. However, older patients displayed a weaker recruitment of CD1c+ MDCs. In vitro studies  
419 have shown that monocytes can differentiate into type I IFN producing monocyte-derived DCs in  
420 response to IAV exposure (47). It is therefore possible that CMs recruited to the nasopharynx in older  
421 individuals preferentially differentiate into IMs rather than DCs. Moreover, CD1c+ DC function is critical  
422 for clearance of IAV infection (35). Therefore, diminished recruitment of CD1c+ MDCs and or reduced  
423 in situ DC differentiation (and therefore delayed or attenuated CD8+ T cell responses) may also  
424 contribute more severe disease in older patients.

425

426 During acute disease, monocytes present in/recruited to the nasopharynx likely contribute to sustained  
427 DC recruitment by secreting  $\text{TNF}\alpha$ , CCL2, CCL3 and CCL7 locally (3, 29, 40). Due to the limited  
428 availability of cells in the NPA samples, demonstrating cytokine secretion from nasopharyngeal cells  
429 was not possible. However, we noted that in the nasopharynx, CMs, CD1c+ MDCs and CD141+ MDCs  
430 all appeared to mature by upregulating HLA-DR and/or CD86 expression as compared to HCs,  
431 suggesting local activation, likely in response to the inflammatory milieu and/or virus exposure. CD86,  
432 a critical costimulatory molecule and ligand for CD28 and CTLA-4, is upregulated on monocytes and  
433 DCs upon virus infection in vitro and in vivo (48). Lower expression of CD86 on circulating myeloid cells  
434 as compared to nasopharyngeal cells during IAV infection suggests migration of mature cells to the  
435 nasopharynx, and/or *in situ* differentiation of monocytes to induced-DCs (that may not upregulate  
436 maturation markers) in blood during acute IAV infection as previously speculated (47). A non-human  
437 primate model of chronic simian immunodeficiency virus (SIV) infection revealed sustained mobilization  
438 of MDCs from the bone marrow via blood to the intestinal mucosa, where MDCs remained activated  
439 and eventually underwent apoptosis (49). In IAV infection, monocytes and DCs are likely recruited to  
440 the nasopharynx for a shorter period of time, where they face a similar fate. Some DCs likely traffic  
441 antigens to the lymph node to support adaptive responses (21, 35).

442  
443 Nasopharyngeal CMs were also more mature in patients with higher viral RNA loads and their  
444 recruitment and/or differentiation may be aided by local cytokine production ( $\text{TNF}\alpha$  and IL-6). Key innate  
445 inflammatory cytokines, including  $\text{TNF}\alpha$ , IL-6,  $\text{IFN}\alpha$ , IL-10, IL-15, and IL-18, were all significantly  
446 elevated early during infection (days 1-5) compared to healthy controls.  $\text{TNF}\alpha$  levels strongly correlated  
447 with the presence of CMs in both blood and nasopharynx; despite the significant expansion of IMs in  
448 blood, supporting previous studies (2, 14, 31, 50). We also demonstrated that be circulating CMs was  
449 the most frequent cellular source of  $\text{TNF}\alpha$  among blood monocytes and DCs, while the  $\text{TNF}\alpha$  at the site  
450 of infection may come from both CMs and the IMs (both subsets found in increased frequencies). *Ex*  
451 *vivo*, at steady state, human blood CMs and IMs have comparable  $\text{TNF}\alpha$  secretion irrespective of the  
452 nature of stimulation (14). IAV infection, therefore, may skew monocyte subset function, in addition to  
453 monocyte distribution and maturation. The broad range of  $\text{TNF}\alpha$ , IL-6 and  $\text{IFN}\alpha$  responses seem among  
454 the IAV patients suggest that seasonal IAV strains are associated with milder cytokine responses than  
455 those observed during infections with 2009 H1N1 pandemic influenza or highly pathogenic avian H5N1



456 strains (3, 10, 31, 51). Within the setting of seasonal influenza however, older patients had more IMs in  
457 the NPA and displayed stronger TNF $\alpha$  responses, locally and systemically.

458

459 During IAV infection, the significant expansion of IMs in blood and the nasopharynx could be mediated  
460 by the presence of CCL2, a chemokine critical for monocyte chemotaxis (52). Upon CCL2 ligation, CCR2  
461 facilitates CM and IM adhesion and transmigration from blood to tissues (53). Therefore, in IAV patients,  
462 CCL2 may contribute to recruitment of monocytes and DCs from circulation to the nasopharynx to aid  
463 inflammation (3, 50). Furthermore, elevated IFN $\alpha$  in circulation correlated with reduced viral RNA load,  
464 although we saw no evidence of this locally at the site of infection; suggesting that perhaps lower  
465 systemic IFN responses can indicate impaired control of viral replication in the nasopharynx, as  
466 previously reported (31). This finding also supports previous studies showing that attenuated RIG-I  
467 signalling impairs IFN responses in the elderly (54) and very young (55), both groups at high risk of  
468 influenza-associated mortality.

469

470 During convalescence, monocyte and DC frequencies, and cytokine levels normalized in blood and the  
471 nasopharynx to levels seen in healthy individuals. The local and systemic inflammation observed,  
472 therefore, appears limited to the acute phase of disease and wanes during convalescence. Unlike  
473 patients infected with the pandemic 2009 H1N1 IAV strain, where long lasting immune perturbations  
474 were documented (28); the repercussions of relatively mild seasonal IAV infections appear short-lived.  
475 This is also in contrast to in vivo studies which demonstrated prolonged DC activation and disruption of  
476 DC subset reconstitution in the lungs following IAV infection (56).

477

478 In April-May 2020, during the COVID-19 pandemic, the approach and methods described here allowed  
479 us to implement this study plan in a rapidly evolving pandemic. Although the patient cohorts were not  
480 identical, this endeavour proved the feasibility of using nasopharyngeal aspiration to assess local  
481 immune responses during respiratory viral infections. We observed that patients with IBV, RSV or  
482 SARS-CoV-2 also displayed an influx of cells to the nasopharynx during infection. Despite annual  
483 reoccurrence of IBV and RSV infections, detailed investigations of the innate cells at the site of infection  
484 in patients are quite rare (29, 30), and the technique we describe allows for minimally invasive  
485 longitudinal measurement of cellular and molecular aspects of infection. Patients with mild SARS-CoV-

486 2 infection have not been studied as extensively as patients with severe or fatal COVID-19. The cell  
487 influx to the nasopharynx in COVID-19 patients did not appear to be due to monocytes but rather due  
488 to CD1c+ MDCs and PDCs, which were reduced in blood, in line with previous reports (41, 57). Also in  
489 line with previous studies (42-44), we found elevated levels of IL-6 in plasma, and also of TNF $\alpha$ . As  
490 different SARS-CoV-2 variants emerge, with concurrently increasing global vaccination rates,  
491 incomplete neutralization and/or protection and herd immunity may result in recurring, mild SARS-CoV-  
492 2 infections. Understanding site-of-infection responses to mild SARS-CoV-2 infections is therefore  
493 increasingly relevant, and can be accomplished by the methods we describe in our study.

494  
495 The present study augments our current understanding of the role of monocyte and DC subsets during  
496 human respiratory viral infections by highlighting unique dynamics and location-specific functions for  
497 each subset over the course of infection. Acute human IAV infection is characterized by an expansion  
498 of IMs and monocyte-mediated cytokinemia driving monocyte and DC migration from blood to the  
499 nasopharynx, the initial site of IAV infection. Older patients with comorbidities display a recruitment  
500 pattern skewed towards IMs and increased TNF rather than CD1c+ MDCs which may contribute to more  
501 severe disease and longer duration of hospitalization observed in these patients. IBV, RSV and mild  
502 SARS-CoV-2 infections elicit different patterns on immune cell recruitment to the nasopharynx as  
503 compared to IAV infections. We also illustrate the value of comparative high-resolution studies of  
504 immune cells in blood and at the site of infection, in order to fully understand their individual contributions  
505 to disease and how they orchestrate inflammation synergistically. Similar studies, carried out  
506 longitudinally across tissues, will aid resolution of these findings, and allow multivariate modelling of  
507 biomarkers of disease severity. Therapeutic approaches which allow selective modulation of monocyte  
508 and DC redistribution, maturation and cytokine/chemokine function may hold the key to reducing  
509 influenza-associated disease burden and mortality in the future.

## 510 **METHODS**

### 511 **Study subjects**

512 Patients seeking medical attention for influenza-like illness at the Emergency Department at the  
513 Karolinska University Hospital in Stockholm, Sweden during three consecutive influenza seasons  
514 (January - March) of 2016-2018 were recruited to the study following informed consent. The inclusion  
515 criteria for enrolment of patients were (1) age >18 years, (2) no known immunodeficiency, (3) not taking  
516 antibiotics, immunomodulatory or anti-inflammatory medication at time of inclusion, (4) presenting with  
517 fever and at least one of the following symptoms of influenza-like illness: cough, nasal congestion,  
518 headache or muscle ache. Convalescent samples were collected after at least 4 weeks, ensuring  
519 absence of respiratory symptoms in the prior week. Healthy volunteers were recruited and sampled  
520 similarly outside of influenza season. During the COVID-19 pandemic, additional patients were included  
521 between April - May 2020 at the Infectious Diseases ward at the Karolinska University Hospital or the  
522 Haga Outpatient Clinic (Haga Närakut) in Stockholm, Sweden, as well as mild/asymptomatic household  
523 contacts of patients with confirmed COVID-19 were screened by PCR and enrolled if positive. Clinical  
524 data were obtained from the patients and medical records (Table 1) and are extensively discussed in a  
525 previous publication (58). Total burden of comorbidities was assessed using the CCI (59).

526

527 The severity of disease was categorized using the respiratory domain of the sequential organ failure  
528 assessment score (SOFA) (60). In the absence of arterial partial pressure of oxygen (PaO<sub>2</sub>), peripheral  
529 transcutaneous haemoglobin saturation (SpO<sub>2</sub>) was used instead to calculate a modified SOFA score  
530 (mSOFA) (61). Fraction of inspired oxygen (FiO<sub>2</sub>) estimation based on O<sub>2</sub> flow was done in accordance  
531 with the Swedish Intensive Care register definition (62). Mild disease was defined as PaO<sub>2</sub>/FiO<sub>2</sub> (PFI)  
532 >53 kPa (>400 mmHg) or SpO<sub>2</sub>/FiO<sub>2</sub> (SFI) >400. Moderate disease was defined as PFI >27-53 kPa  
533 (>200-400 mmHg) or SFI 235-400. The disease severity score is more extensively described in a  
534 previous publication (38).

535

### 536 **Sample collection**

537 Blood, nasal swabs and nasopharyngeal aspirates (NPA) were obtained from all patients (acute and  
538 convalescent phase samples) and healthy controls (Figure 1A). Briefly, up to 30mL venous blood was  
539 collected in Vacutainer® tubes containing EDTA, for blood counts and PBMC isolation. Nasopharyngeal

540 swabs (Sigma Virocult®) were collected for diagnostic qPCR. NPA samples were collected into a  
541 vacuum trap by inserting a thin catheter through the naris, deep into the nasopharynx and applying  
542 gentle suction for 1-3 minutes. The vacuum trap and tubing were rinsed out with 3mL sterile PBS. All  
543 samples were processed within 2 hours of sampling.

544

#### 545 **Diagnostic tests to determine etiology of infection**

546 Nasal swab samples were analyzed for influenza A virus (IAV), influenza B virus (IBV) and respiratory  
547 syncytial virus (RSV) by real-time PCR using the commercial Simplexa system™ (63), as well as  
548 bacteria (by culture methods). The tests were performed at the Department of Clinical Microbiology,  
549 Karolinska University Laboratory as part of routine diagnostics for respiratory viral infections. Cycle  
550 threshold (Ct) values from the Simplexa™ assay were considered as semi-quantitative measures of  
551 virus levels in statistical analyses. Bacterial culture results were retrieved wherever available from the  
552 Department of Clinical Microbiology at the Karolinska University Hospital. Convalescent individuals and  
553 healthy controls were confirmed IAV– by qPCR. SARS-CoV-2 infection was diagnosed similarly using  
554 the GeneXpert SARS-CoV-2 detection system (Cepheid). Supplementary data on bacterial cultures  
555 were retrieved from the microbiology lab/clinical records.

556

#### 557 **Isolation of cells from blood and nasopharyngeal aspirates**

558 Blood samples were centrifuged at 800g/10 min/room temperature (RT) and plasma was frozen at –  
559 20°C. The blood volume was reconstituted with sterile PBS and PBMCs were obtained by density-  
560 gradient centrifugation using Ficoll-Paque Plus (GE Healthcare) after centrifugation at 900g/25 min/RT  
561 (without brake). NPA samples were centrifuged at 400g/5 min/RT and the supernatant was frozen at –  
562 20°C. The cells were washed with 5mL sterile PBS to remove mucus, by filtering through a 70µm cell  
563 strainer followed by centrifugation for 400g/5 min/RT. Cell counts and viability were assessed using  
564 Trypan Blue (Sigma) exclusion and an automated Countess cell counter (Invitrogen) or manual counting  
565 using a light microscope (when the counter was unable to distinguish live and dead NPA cells). Cells  
566 were used fresh for flow cytometry (all NPA cells when samples contained  $>10^5$  cells and had  $\geq 70\%$   
567 viability; and at least  $1 \times 10^6$  PBMCs) or frozen in RNALater ( $<10^5$  NPA cells) (ThermoFisher). Excess  
568 PBMCs were cryopreserved in FBS (Gibco) + 10% DMSO (Sigma) and stored in liquid nitrogen.

569

570 **Flow cytometry analysis**

571 Phenotypic analysis was performed on NPA cells and PBMCs using Live/Dead Blue; lineage markers  
572 CD3 (SK7; BD), CD19 (HIB19; Biolegend), CD20 (L27, BD), CD45 (HI30; BD), CD56 (HCD56, BD) and  
573 CD66abce (TET2, Miltenyi Biotec); HLA-DR (TU36, Life technologies), CD14 (M5E2, BD), CD16 (3GE,  
574 Biolegend), CD11c (B-Ly6, BD), CD1c (AD5-8E7; Miltenyi), CD141 (AD5-14H12; Miltenyi), CD123  
575 (7G3; BD); maturation markers CD83 (HB15e, Biolegend) and CD86 (2331; BD); adhesion marker  
576 CD62L (SK11, BD); and migration markers CCR2 (K036C2, Biolegend) and CCR7 (150503; BD); and  
577 fixed with 1% paraformaldehyde for flow cytometry. Samples were acquired on an LSRFortessa flow  
578 cytometer (BD Biosciences) and analyzed using FlowJo software v10 (Tree Star).

579

580 **TNF- $\alpha$  release assay**

581 TNF $\alpha$  secretion from fresh PBMCs in response to TLR stimulation was assessed using the TNF- $\alpha$   
582 Secretion Assay-Detection Kit (PE) (130-091-268, Miltenyi Biotec) according to the manufacturer's  
583 instructions. TNF $\alpha$  secretion was measured over 2 hours of incubation at 37°C with shaking (200 rpm)  
584 in the presence or absence of 1  $\mu$ g/mL 3M-019 (7/8L) (Invivogen). Briefly, the capture antibody  
585 immobilized all secreted TNF $\alpha$  on the surface of the cell, and the detection antibody (PE-labelled) was  
586 incorporated into the above panel of antibodies to determine the cellular source of TNF $\alpha$ . Secretion of  
587 TNF $\alpha$  was quantified using flow cytometry.

588

589 **ELISA and Luminex**

590 Plasma samples and NPA supernatants were assayed for soluble markers using ELISA and Luminex.  
591 Human IFN $\alpha$  All Subtype ELISA was performed according to the manufacturer's instructions (PBL Assay  
592 Science). TNF $\alpha$  and IL-6 ELISAs were performed using DuoSet® kits (R&D Systems). Luminex assays  
593 were performed using custom-designed 9-plex (IFN $\gamma$ , IL-8, IL-10, IL-18, CCL2, CCL3, CCL7, IL-1 $\beta$  and  
594 IL-12p70) kit (R&D Systems) and analyzed on the Bio-Plex® 200 instrument (Bio-Rad).

595

596 **Statistics**

597 Data were analyzed using GraphPad Prism version 6.0 (GraphPad Software) and JMP®, version 14.2.  
598 (SAS Institute Inc., Cary, NC, 1989-2019). Differences between frequencies in IAV patients and HCs  
599 were assessed using nonparametric tests after assessing normality, using the Mann-Whitney test (at

600 95% confidence intervals). For comparisons between exposure conditions, two-way ANOVA with  
601 Sidak's multiple comparisons test was applied. For comparisons between acute and convalescent  
602 phase data, Wilcoxon matched-pairs signed rank test was used. Bivariate and multivariate linear  
603 regression analysis was performed using JMP®, choosing Spearman's rank correlation coefficient for  
604 nonparametric analyses. Differences between HCs or IAV patients and other patient groups were  
605 assessed using nonparametric tests after assessing normality, using the Kruskal-Wallis test with Dunn's  
606 multiple comparisons test (at 95% confidence intervals). Data were considered significant at  $p < 0.05$ .

607

#### 608 **Study approval**

609 Informed consent was obtained from all patients and volunteers following verbal and written information.  
610 The study was approved by the Swedish Ethical Review Authority (No. 2015/1949-31/4) and performed  
611 according to the Declaration of Helsinki.

612 **ADDITIONAL SUPPLEMENTARY MATERIAL**

<b>Supplementary Table - Flow cytometry panels</b>			
Panel 1: Phenotyping of MNPs from PBMCs			
<b>Fluorochrome</b>	<b>Marker</b>	<b>Company</b>	<b>Clone</b>
FITC	CD83	Biolegend	HB15e
PerCp Cy5.5	CD123	BD	7G3
PE Cy7	CD1c	Miltenyi	AD5-8E7
PE Cy5	CD11c	BD	B-Ly6
PE TR	HLA-DR	Life Technologies	TU36
PE	CD141	Miltenyi	AD5-14H12
APC-Cy7	CD3	BD	SK7
	CD19	BioLegend	HIB19
	CD20	BD	L27
	CD56	BD	HCD56
	CD66abce	Miltenyi	TET2
AF700	CD16	BioLegend	3GE
APC	CD45	BD	HI30
BV786	CD62L	BD	SK11
BV650	CD86	BD	2331
BV605	CCR2	BioLegend	K036C2
BV510	CD14	BD	M5E2
V450	CCR7	BD	150503
DAPI	Live/Dead Blue	Thermo Fisher	Cat no: L34962

Panel 2: Phenotyping of PBMCs following TLR stimulation- TNF-release assay			
<b>Fluorochrome</b>	<b>Marker</b>	<b>Company</b>	<b>Clone</b>
FITC	CD83	Biolegend	HB15e
PerCp Cy5.5	CD123	BD	7G3
PE Cy7	CD1c	Miltenyi	AD5-8E7
PE Cy5	CD11c	BD	B-Ly6
PE TR	HLA-DR	Life Technologies	TU36
PE	<b>TNF-<math>\alpha</math> Detection Antibody</b>	Miltenyi	(Reagent from 130-091-268)
APC-Cy7	CD3	BD	SK7
	CD19	BioLegend	HIB19
	CD20	BD	L27
	CD56	BD	HCD56
	CD66abce	Miltenyi	TET2
AF700	CD16	BioLegend	3GE
APC	CD141	Miltenyi	AD5-14H12
BV786	CD62L	BD	SK11
BV650	CD86	BD	2331
BV605	CCR2	BioLegend	K036C2
BV510	CD14	BD	M5E2
V450	CCR7	BD	150503
DAPI	Live/Dead Blue	Thermo Fisher	Cat no: L34962

613

614 **Supplementary Table 1. Flow cytometry panels.**

615 **ACKNOWLEDGMENTS**

616 We thank the patients and healthy volunteers who have contributed clinical material to this study. We  
617 would like to thank Adeline Mawa, Kevin Fallahi, Marcus Nordin, Roosa Vaitiniemi, Eric Åhlberg and the  
618 research nurses at the Emergency and Infectious Diseases Departments for technical assistance. This  
619 work was supported by grants to AS-S from the Swedish Research Council (VR), the Swedish Heart-  
620 Lung Foundation, the Bill and Melinda Gates Foundation, the Swedish Childhood Cancer Fund and  
621 Karolinska Institutet.



622 **AUTHOR CONTRIBUTIONS**

623 SV, NJ, AF and AS-S planned the study. SV, MY, SF-J and SL performed experiments. SF-J, BÖ, KS,  
624 AF and NJ included and sampled patients, and collected clinical data. JA provided relevant  
625 pseudonymized patient clinical data. SV, MY, SF-J, BÖ, SL, MA and AS-S analyzed data. SV and AS-  
626 S prepared figures and wrote the manuscript. All co-authors edited the manuscript.

627 **DISCLOSURES**

628 AS-S is a consultant to Astra-Zeneca on studies not related to the present study.


## 629 REFERENCES

- 630 1. WHO. Factsheet: Influenza (Seasonal). 2018.
- 631 2. Cole SL, Dunning J, Kok WL, Benam KH, Benlahrech A, Repapi E, et al. M1-like monocytes are a major  
632 immunological determinant of severity in previously healthy adults with life-threatening influenza. *JCI Insight*.  
633 2017;2(7):e91868.
- 634 3. Oshansky CM, Gartland AJ, Wong SS, Jeevan T, Wang D, Roddam PL, et al. Mucosal immune responses  
635 predict clinical outcomes during influenza infection independently of age and viral load. *Am J Respir Crit Care*  
636 *Med*. 2014;189(4):449-62.
- 637 4. Kuiken T, Taubenberger JK. Pathology of human influenza revisited. *Vaccine*. 2008;26:D59-D66.
- 638 5. Kuiken T, van den Brand J, van Riel D, Pantin-Jackwood M, Swayne DE. Comparative pathology of select  
639 agent influenza a virus infections. *Vet Pathol*. 2010;47(5):893-914.
- 640 6. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients  
641 with COVID-19 in Wuhan, China: a retrospective cohort study. *The Lancet*. 2020;395(10229):1054-62.
- 642 7. Tellier R. Review of Aerosol Transmission of Influenza A Virus. *Emerg Infect Dis*. 2006;12(11):1657-62.
- 643 8. Sanders CJ, Doherty PC, Thomas PG. Respiratory epithelial cells in innate immunity to influenza virus  
644 infection. *Cell Tissue Res*. 2011;343(1):13-21.
- 645 9. Stramer SL, Collins C, Nugent T, Wang X, Fuschino M, Heitman JW, et al. Sensitive detection assays for  
646 influenza RNA do not reveal viremia in US blood donors. *J Infect Dis*. 2012;205(6):886-94.
- 647 10. Sakabe S, Iwatsuki-Horimoto K, Takano R, Nidom CA, Le M, Nagamura-Inoue T, et al. Cytokine  
648 production by primary human macrophages infected with highly pathogenic H5N1 or pandemic H1N1 2009  
649 influenza viruses. *J Gen Virol*. 2011;92(Pt 6):1428-34.
- 650 11. Wang J, Nikrad MP, Travanty EA, Zhou B, Phang T, Gao B, et al. Innate immune response of human  
651 alveolar macrophages during influenza A infection. *PLoS One*. 2012;7(3):e29879.
- 652 12. Kwissa M, Nakaya HI, Onlamoon N, Wrarmert J, Villingner F, Perng GC, et al. Dengue virus infection  
653 induces expansion of a CD14(+)CD16(+) monocyte population that stimulates plasmablast differentiation. *Cell*  
654 *Host Microbe*. 2014;16(1):115-27.
- 655 13. Sporri R, Reis e Sousa C. Inflammatory mediators are insufficient for full dendritic cell activation and  
656 promote expansion of CD4+ T cell populations lacking helper function. *Nat Immunol*. 2005;6(2):163-70.
- 657 14. Boyette LB, Macedo C, Hadi K, Elinoff BD, Walters JT, Ramaswami B, et al. Phenotype, function, and  
658 differentiation potential of human monocyte subsets. *PLoS One*. 2017;12(4):e0176460.
- 659 15. Jakubzick C, Gautier EL, Gibbings SL, Sojka DK, Schlitzer A, Johnson TE, et al. Minimal differentiation of  
660 classical monocytes as they survey steady-state tissues and transport antigen to lymph nodes. *Immunity*.  
661 2013;39(3):599-610.
- 662 16. Patel AA, Zhang Y, Fullerton JN, Boelen L, Rongvaux A, Maini AA, et al. The fate and lifespan of human  
663 monocyte subsets in steady state and systemic inflammation. *J Exp Med*. 2017;214(7):1913-23.
- 664 17. Fingerle G, Pforte A, Passlick B, Blumenstein M, Strobel M, Ziegler-Heitbrock L. The novel subset of  
665 CD14+:CD16+ blood monocytes is expanded in sepsis patients. *Blood*. 1993;82(10):3170-6.
- 666 18. Tisoncik JR, Korth MJ, Simmons CP, Farrar J, Martin TR, Katze MG. Into the Eye of the Cytokine Storm.  
667 *Microbiol Mol Biol R*. 2012;76(1):16-32.
- 668 19. Hemont C, Neel A, Heslan M, Braudeau C, Josien R. Human blood mDC subsets exhibit distinct TLR  
669 repertoire and responsiveness. *J Leukoc Biol*. 2013;93(4):599-609.
- 670 20. Jongbloed SL, Kassianos AJ, McDonald KJ, Clark GJ, Ju X, Angel CE, et al. Human CD141+ (BDCA-3)+  
671 dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. *J Exp Med*.  
672 2010;207(6):1247-60.
- 673 21. Cella M, Jarrossay D, Facchetti F, Alebardi O, Nakajima H, Lanzavecchia A, et al. Plasmacytoid monocytes  
674 migrate to inflamed lymph nodes and produce large amounts of type I interferon. *Nat Med*. 1999;5(8):919-23.
- 675 22. Baharom F, Thomas S, Rankin G, Lepzien R, Pourazar J, Behndig AF, et al. Dendritic Cells and Monocytes  
676 with Distinct Inflammatory Responses Reside in Lung Mucosa of Healthy Humans. *J Immunol*. 2016;196(11):4498-  
677 509.
- 678 23. Alcantara-Hernandez M, Leylek R, Wagar LE, Engleman EG, Keler T, Marinkovich MP, et al. High-  
679 Dimensional Phenotypic Mapping of Human Dendritic Cells Reveals Interindividual Variation and Tissue  
680 Specialization. *Immunity*. 2017;47(6):1037-50 e6.
- 681 24. Smed-Sorensen A, Chalouni C, Chatterjee B, Cohn L, Blattmann P, Nakamura N, et al. Influenza A virus  
682 infection of human primary dendritic cells impairs their ability to cross-present antigen to CD8 T cells. *PLoS*  
683 *Pathog*. 2012;8(3):e1002572.


- 684 25. Diao H, Cui G, Wei Y, Chen J, Zuo J, Cao H, et al. Severe H7N9 infection is associated with decreased  
685 antigen-presenting capacity of CD14+ cells. *PLoS One*. 2014;9(3):e92823.
- 686 26. Baharom F, Thomas S, Bieder A, Hellmer M, Volz J, Sandgren KJ, et al. Protection of human myeloid  
687 dendritic cell subsets against influenza A virus infection is differentially regulated upon TLR stimulation. *J*  
688 *Immunol*. 2015;194(9):4422-30.
- 689 27. Jochems SP, Marcon F, Carniel BF, Holloway M, Mitsi E, Smith E, et al. Inflammation induced by influenza  
690 virus impairs human innate immune control of pneumococcus. *Nat Immunol*. 2018;19(12):1299-308.
- 691 28. Lichtner M, Mastroianni CM, Rossi R, Russo G, Belvisi V, Marocco R, et al. Severe and persistent  
692 depletion of circulating plasmacytoid dendritic cells in patients with 2009 pandemic H1N1 infection. *PLoS One*.  
693 2011;6(5):e19872.
- 694 29. Gill MA, Long K, Kwon T, Muniz L, Mejias A, Connolly J, et al. Differential recruitment of dendritic cells  
695 and monocytes to respiratory mucosal sites in children with influenza virus or respiratory syncytial virus infection.  
696 *J Infect Dis*. 2008;198(11):1667-76.
- 697 30. Gill MA, Palucka KA, Barton T, Ghaffar F, Jafri H, Banchereau J, et al. Mobilization of Plasmacytoid and  
698 Myeloid Dendritic Cells to Mucosal Sites in Children with Respiratory Syncytial Virus and Other Viral Respiratory  
699 Infections. *J Infect Dis*. 2005;2005(191):1105-15.
- 700 31. Dunning J, Blankley S, Hoang LT, Cox M, Graham CM, James PL, et al. Progression of whole-blood  
701 transcriptional signatures from interferon-induced to neutrophil-associated patterns in severe influenza. *Nat*  
702 *Immunol*. 2018;19(6):625-35.
- 703 32. Vangeti S, Gertow J, Yu M, Liu S, Baharom F, Scholz S, et al. Human Blood and Tonsil Plasmacytoid  
704 Dendritic Cells Display Similar Gene Expression Profiles but Exhibit Differential Type I IFN Responses to Influenza  
705 A Virus Infection. *J Immunol*. 2019;202(7):2069-81.
- 706 33. McGill J, Van Rooijen N, Legge KL. Protective influenza-specific CD8 T cell responses require interactions  
707 with dendritic cells in the lungs. *J Exp Med*. 2008;205(7):1635-46.
- 708 34. Mount AM, Belz GT. Mouse Models of Viral Infection: Influenza Infection in the Lung. In: Naik S, editor.  
709 *Dendritic Cell Protocols Methods in Molecular Biology (Methods and Protocols)*. 595: Humana Press. ; 2010. p.  
710 299-318.
- 711 35. GeurtsvanKessel CH, Willart MA, van Rijt LS, Muskens F, Kool M, Baas C, et al. Clearance of influenza  
712 virus from the lung depends on migratory langerin+CD11b- but not plasmacytoid dendritic cells. *J Exp Med*.  
713 2008;205(7):1621-34.
- 714 36. Segura E, Durand M, Amigorena S. Similar antigen cross-presentation capacity and phagocytic functions  
715 in all freshly isolated human lymphoid organ-resident dendritic cells. *J Exp Med*. 2013;210(5):1035-47.
- 716 37. Mick E, Kamm J, Pisco AO, Ratnasiri K, Babik JM, Castaneda G, et al. Upper airway gene expression  
717 reveals suppressed immune responses to SARS-CoV-2 compared with other respiratory viruses. *Nat Commun*.  
718 2020;11(1):5854.
- 719 38. Falck-Jones S, Vangeti S, Yu M, Falck-Jones R, Cagigi A, Badolati I, et al. Functional monocytic myeloid-  
720 derived suppressor cells increase in blood but not airways and predict COVID-19 severity. *J Clin Invest*.  
721 2021;131(6).
- 722 39. Cagigi A, Yu M, Österberg B, Svensson J, Falck-Jones S, Vangeti S, et al. Airway antibodies emerge  
723 according to COVID-19 severity and wane rapidly but reappear after SARS-CoV-2 vaccination. *JCI Insight*. 2021.
- 724 40. Marion T, Elbahesh H, Thomas PG, DeVincenzo JP, Webby R, Schughart K. Respiratory Mucosal  
725 Proteome Quantification in Human Influenza Infections. *PLoS One*. 2016;11(4):e0153674.
- 726 41. Zingaropoli MA, Nijhawan P, Carraro A, Pasculli P, Zuccala P, Perri V, et al. Increased sCD163 and sCD14  
727 Plasmatic Levels and Depletion of Peripheral Blood Pro-Inflammatory Monocytes, Myeloid and Plasmacytoid  
728 Dendritic Cells in Patients With Severe COVID-19 Pneumonia. *Front Immunol*. 2021;12:627548.
- 729 42. Del Valle DM, Kim-Schulze S, Huang HH, Beckmann ND, Nirenberg S, Wang B, et al. An inflammatory  
730 cytokine signature predicts COVID-19 severity and survival. *Nat Med*. 2020;26(10):1636-43.
- 731 43. Merad M, Martin JC. Pathological inflammation in patients with COVID-19: a key role for monocytes and  
732 macrophages. *Nat Rev Immunol*. 2020;20(6):355-62.
- 733 44. Mudd PA, Crawford JC, Turner JS, Souquette A, Reynolds D, Bender D, et al. Distinct inflammatory  
734 profiles distinguish COVID-19 from influenza with limited contributions from cytokine storm. *Sci Adv*. 2020;6(50).
- 735 45. Herold S, von Wulffen W, Steinmueller M, Pleschka S, Kuziel WA, Mack M, et al. Alveolar epithelial cells  
736 direct monocyte transepithelial migration upon influenza virus infection: impact of chemokines and adhesion  
737 molecules. *J Immunol*. 2006;177(3):1817-24.
- 738 46. Patin E, Hasan M, Bergstedt J, Rouilly V, Libri V, Urrutia A, et al. Natural variation in the parameters of  
739 innate immune cells is preferentially driven by genetic factors. *Nat Immunol*. 2018;19(3):302-14.

- 740 47. Cao W, Taylor AK, Biber RE, Davis WG, Kim JH, Reber AJ, et al. Rapid differentiation of monocytes into  
741 type I IFN-producing myeloid dendritic cells as an antiviral strategy against influenza virus infection. *J Immunol.*  
742 2012;189(5):2257-65.
- 743 48. Hubo M, Trinschek B, Kryczanowsky F, Tuettenberg A, Steinbrink K, Jonuleit H. Costimulatory molecules  
744 on immunogenic versus tolerogenic human dendritic cells. *Front Immunol.* 2013;4:82.
- 745 49. Wijewardana V, Kristoff J, Xu C, Ma D, Haret-Richter G, Stock JL, et al. Kinetics of myeloid dendritic cell  
746 trafficking and activation: impact on progressive, nonprogressive and controlled SIV infections. *PLoS Pathog.*  
747 2013;9(10):e1003600.
- 748 50. Sprenger HM, R.G.; Kaufmann, A.; Bussfeld, D.; Rischkowsky, E.; Gemsa, D. Selective induction of  
749 monocyte and not neutrophil-attracting chemokines after influenza A virus infection. *J Exp Med.* 1996;184:1191-  
750 6.
- 751 51. Gerlach RL, Camp JV, Chu YK, Jonsson CB. Early host responses of seasonal and pandemic influenza A  
752 viruses in primary well-differentiated human lung epithelial cells. *PLoS One.* 2013;8(11):e78912.
- 753 52. Dean RA, Cox JH, Bellac CL, Doucet A, Starr AE, Overall CM. Macrophage-specific metalloelastase (MMP-  
754 12) truncates and inactivates ELR+ CXC chemokines and generates CCL2, -7, -8, and -13 antagonists: potential  
755 role of the macrophage in terminating polymorphonuclear leukocyte influx. *Blood.* 2008;112(8):3455-64.
- 756 53. Tsou CL, Peters W, Si Y, Slaymaker S, Aslanian AM, Weisberg SP, et al. Critical roles for CCR2 and MCP-3  
757 in monocyte mobilization from bone marrow and recruitment to inflammatory sites. *J Clin Invest.*  
758 2007;117(4):902-9.
- 759 54. Molony RD, Nguyen JT, Kong Y, Montgomery RR, Shaw AC, Iwasaki A. Aging impairs both primary and  
760 secondary RIG-I signaling for interferon induction in human monocytes. *Sci Signal.* 2017;10.
- 761 55. Marr N, Wang TI, Kam SH, Hu YS, Sharma AA, Lam A, et al. Attenuation of respiratory syncytial virus-  
762 induced and RIG-I-dependent type I IFN responses in human neonates and very young children. *J Immunol.*  
763 2014;192(3):948-57.
- 764 56. Strickland DH, Fear V, Shenton S, Wikstrom ME, Zosky G, Larcombe AN, et al. Persistent and  
765 compartmentalised disruption of dendritic cell subpopulations in the lung following influenza A virus infection.  
766 *PLoS One.* 2014;9(11):e111520.
- 767 57. Peruzzi B, Bencini S, Capone M, Mazzoni A, Maggi L, Salvati L, et al. Quantitative and qualitative  
768 alterations of circulating myeloid cells and plasmacytoid DC in SARS-CoV-2 infection. *Immunology.*  
769 2020;161(4):345-53.
- 770 58. ACP. Normal Laboratory Values 2018. Available from:  
771 <http://idgateway.wustl.edu/Normal%20lab%20values.pdf>.
- 772 59. Charlson M, Pompei P, Ales K, MacKenzie C. A new method of classifying prognostic comorbidity in  
773 longitudinal studies- development and validation. *J Chronic Dis.* 1987;40(5):373-83.
- 774 60. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, et al. The SOFA (Sepsis-related  
775 Organ Failure Assessment) score to describe organ dysfunction:failure. On behalf of the Working Group on  
776 Sepsis-Related Problems of the European Society of Intensive Care Medicine. *Intensive Care Med.*  
777 1996;22(7):770-10.
- 778 61. Grissom CK, Brown SM, Kuttler KG, Boltax JP, Jones J, Jephson AR, et al. A modified sequential organ  
779 failure assessment score for critical care triage. *Disaster Med Public Health Prep.* 2010;4(4):277-84.
- 780 62. Intensivvårdsregistret S. SIR:s riktlinje för registrering av SOFA. 2018 [Available from:  
781 <https://www.icuregswe.org/globalassets/riktlinjer/sofa.pdf>].
- 782 63. Svensson MJ, Lind I, Wirgart BZ, Ostlund MR, Albert J. Performance of the Simplexa Flu A/B & RSV Direct  
783 Kit on respiratory samples collected in saline solution. *Scand J Infect Dis.* 2014;46(12):825-31.
- 784


A




B




C





D




E






















Supplementary figure 1


A




B



C



D



**Table 1. Patient and control characteristics**

<b>Cohort</b>	<b>IAV</b>	<b>IBV</b>	<b>RSV</b>	<b>SARS-CoV-2</b>	<b>HC</b>	<b>Sig.<sup>A</sup></b>
<i>n</i>	40	10	6	8	16	
Age, mean (range)	59 (20-98)	53 (25-89)	61 (32-88)	44 (29-66)	46 (28-59)	0.068
Male gender, <i>n</i> (%)	18 (45)	6 (60)	2 (33)	4 (50)	8 (50)	0.9
Onset to inclusion, days, mean (SD)	3.3 (2.1)	5.0 (1.3)	6.5 (2.6)	13.2 (7.8)	-	<0.001
Hospital admission, <i>n</i> (%)	15 (38)	2 (20)	4 (67)	2 (25)	-	0.3
<b>Co-morbidities</b>						
CCI, mean (SD)	2.46 (2.22)	1.44 (1.81)	3.50 (3.83)	0.88 (1.36)	-	0.12
BMI, mean (SD)	27.1 (4.8)	26.5 (5.8)	26.5 (4.7)	26.1 (3.6)	-	>0.9
Hypertension, <i>n</i> (%)	9 (22)	1 (10)	2 (33)	2 (25)	-	0.7
Diabetes, <i>n</i> (%)	3 (7.5)	2 (20)	2 (33)	2 (25)	-	0.1
Current smoker, <i>n</i> (%)	5 (14)	1 (11)	0	0	-	>0.9
<b>Laboratory analyses</b>						
CRP (mg/L), mean (SD)	41 (35)	60 (85)	47 (21)	26 (37)	1 (1)	0.009
WBC (x10 <sup>9</sup> /L), mean (SD)	7.07 (2.45)	7.00 (2.92)	8.78 (2.49)	5.67 (2.24)	6.24 (1.28)	0.14
Lymphocytes (x10 <sup>9</sup> /L), mean (SD)	1.08 (0.86)	0.89 (0.33)	1.1 (NA)	1.64 (0.67)	1.7 (0.37)	0.2
Neutrophils (x10 <sup>9</sup> /L), mean (SD)	5.14 (2.18)	5.41 (3.13)	5.6 (NA)	3.19 (1.85)	3.62 (1.21)	0.3
Monocytes (x10 <sup>9</sup> /L), mean (SD)	0.75 (0.32)	0.53 (0.11)	0.8 (NA)	0.56 (0.23)	0.45 (0.06)	0.14
Ct-value, mean (SD)	27.0 (6.1)	27.8 (7.1)	30.9 (6.0)	25.4 (5.8)	-	0.4
<b>Treatment</b>						
Tamiflu prescribed, <i>n</i> (%)	18 (45)	0	0	0	-	-
Antibiotics prescribed, <i>n</i> (%)	8 (21)	2 (22)	3 (50)	0	-	0.3
<b>Peak severity score</b>						
Mild disease, <i>n</i> (%)	34 (85)	10 (100)	4 (67)	7 (88)	-	0.3
Moderate disease, <i>n</i> (%)	6 (15)	0	2 (33)	1 (12)	-	0.3

<sup>A</sup> Statistical tests performed: One-way ANOVA; Fisher's exact test